In India, Proteinuria is quite common, occurring in upto 50% of patients, resulting in decreased patient survival and increased prevalence of cardiovascular disease. ACE inhibitors (ACEI) & Angiotensin receptor blockers (ARB) have been the mainstay of therapy in native kidney proteinuria, though may not succeed in all patients because of side effects. Pentoxyfylline has been advocated as an anti-inflammatory measure, probably contributing to amelioration of proteinuria. Decreasing proteinuria is the mainstay of therapy in order to delay the progression of CKD. Burden of disease Diabetic nephropathy (DN) is the main cause of endstage renal disease (ESRD). Diabetic Nephropathy is the leading cause of DM-related morbidity and mortality. Both microalbuminuria and macroalbuminuria in individuals with DM are associated with increased risk of cardiovascular disease.Prevalence of diabetic nephropathy in INDIA- 30.3%.